1. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors
- Author
-
P, Malherbe, F, Knoflach, M C, Hernandez, T, Hoffmann, P, Schnider, R H, Porter, J G, Wettstein, T M, Ballard, W, Spooren, and L, Steward
- Subjects
Male ,Pyridines ,Guinea Pigs ,Benzeneacetamides ,Action Potentials ,Aminopyridines ,In Vitro Techniques ,Substance P ,Ligands ,Mice ,Neurokinin-1 Receptor Antagonists ,Mesencephalon ,Animals ,Humans ,Phosphorylation ,Neurons ,Dose-Response Relationship, Drug ,Receptors, Neurokinin-3 ,Receptors, Neurokinin-1 ,Amides ,Research Papers ,Rats ,Substantia Nigra ,Macaca fascicularis ,HEK293 Cells ,Schizophrenia ,Female ,Gerbillinae ,Inositol ,Antipsychotic Agents - Abstract
Clinical results of osanetant and talnetant (selective-NK₃ antagonists) indicate that blocking the NK₃ receptor could be beneficial for the treatment of schizophrenia. The objective of this study was to characterize the in vitro and in vivo properties of a novel dual NK₁/NK₃ antagonist, RO4583298 (2-phenyl-N-(pyridin-3-yl)-N-methylisobutyramide derivative).RO4583298 in vitro pharmacology was investigated using radioligand binding ([³H]-SP, [³H]-osanetant, [³H]-senktide), [³H]-inositol-phosphate accumulation Schild analysis (SP- or [MePhe⁷]-NKB-induced) and electrophysiological studies in guinea-pig substantia nigra pars compacta (SNpc). The in vivo activity of RO4583298 was assessed using reversal of GR73632-induced foot tapping in gerbils (GFT; NK₁) and senktide-induced tail whips in mice (MTW; NK₃).RO4583298 has a high-affinity for NK₁ (human and gerbil) and NK₃ (human, cynomolgus monkey, gerbil and guinea-pig) receptors and behaves as a pseudo-irreversible antagonist. Unusually it binds with high-affinity to mouse and rat NK₃, yet with a partial non-competitive mode of antagonism. In guinea-pig SNpc, RO4583298 inhibited the senktide-induced potentiation of spontaneous activity of dopaminergic neurones with an apparent non-competitive mechanism of action. RO4583298 (p.o.) robustly blocked the GFT response, and inhibited the MTW.RO4583298 is a high-affinity, non-competitive, long-acting in vivo NK₁/NK₃ antagonist; hence providing a useful in vitro and in vivo pharmacological tool to investigate the roles of NK₁ and NK₃ receptors in psychiatric disorders.
- Published
- 2010